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Abstract 
 
Background: Multiple sclerosis (MS) is believed to be an autoimmune disease that 
creates an inflammatory process that breaks down the blood brain barrier (BBB) allowing 
the immune system to attack the myelin sheaths of the central nervous system (CNS). MS 
can be treated with a variety of disease modifying drugs (DMD) that decrease the 
immune system’s attack on the myelin sheaths of the CNS.  In the past few decades, 
three-hydroxy-three-methylglutaryl coenzyme A reductase inhibitors, known as statins, 
have been suggested to have anti-inflammatory effects that will reduce the permeability 
of the BBB. This review is to investigate the trials that have been done involving the use 
of statins as monotherapy, or in combination with an interferon DMD, as treatment in 
relapse-remitting MS (RRMS). 
Methods: An extensive review of MEDLINE, CINAHL, Web of Science, and 
MDConsult, was performed to find human trials that used statins with or without beta 
interferons to treat RRMS. The research also looked for the trials that measured the 
number of contrasted enhanced lesions on T1 sequenced magnetic resonance imaging.  
Results: The three trials reviewed had differing results. The Birnbaum et al trial 
concluded that statins may have an adverse effect on the disease activity of RRMS and 
should be used with caution. The Paul et al trial concluded that statins were safe, well 
tolerated, and had possible benefits in treating RRMS. The Rudick et al trial concluded 
that statins did not affect the treatment of RRMS. 
Conclusion: The question of how effective statins are in the treatment of RRMS, is yet to 
be resolved. There is a need for large population trials with of long duration that focus 
their outcomes on the clinical aspect of treating RRMS. 
Keywords: Multiple Sclerosis, Statins, and magnetic resonance imaging 
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The Efficacy of Statins in Treating Relapse-Remission Multiple 
Sclerosis 
 
 
BACKGROUND   
 
Multiple Sclerosis 
 
 Multiple sclerosis (MS) is an incurable disease of the central nervous system (CNS) 
and, possibly, one of the most frequently diagnosed neurological diseases in young 
adults. As of May 2009, there are about 400 000 individuals in the US with MS and about 
10 000 newly diagnosed cases every year.1 Although MS is not terminal, it can be 
debilitating to the point that the patients are unable to care for themselves.  
 MS is believed to be an autoimmune disease in which the leukocytes that are meant to 
fight disease begin to attack the myelin sheaths of the nerves within the CNS.1 Normally 
the blood brain barrier (BBB) will provide immune privileges and homeostasis to the 
CNS, but an immunological event, early in MS, breaks down the BBB and allows 
transmigration of antigen and non-antigen specific leukocytes as well as immunological 
mediators.2, 3 Once across the BBB, the leukocytes begin to attack, causing an 
inflammatory process that will eventually lead to the destruction of the myelin sheaths.  
 There are several diagnostic subcategories for MS (Table 1), and they are based on a 
state of progression versus relapse-remitting. The primary and secondary progressive 
states deal with accumulation of symptoms that changes the baseline of the patient’s 
disability. The relapse-remitting state is an exacerbation that will remit back to the 
patient’s disability base line from before the exacerbation. There are patients who can 
have aspects of both progressive and relapse-remitting multiple sclerosis (RRMS).1  
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 MS is treated with a variety of disease-modifying drugs (DMD). Glatiramer acetate, 
motroxantrone, beta-interferons (INF-β), and natalizumab are DMDs that have been 
proven to reduce relapse, and have been FDA approved for RRMS. Even though these 
can help to reduce relapse, they do not stay the progression of MS. The downside to these 
drugs, the need for treatment for duration of life and the side effects, can cause many 
patients to refuse long-term adherence to the treatment.5  DMDs are used to reduce the 
immune system’s attack on the myelin sheaths. Researchers are continually looking for 
drugs that will either improve the remitting time or stay the progression.  
Statins 
 Three-hydroxy-three-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
known as statins, were first approved by the FDA in August of 1987. In 1995, 
Kobashigawa et al6 reported that post cardiac transplant patients had improved outcomes 
when treated with pravastatin. These findings led to studies that extensively explored 
statins and their potential in the treatment of autoimmune diseases.7 
 Experimental autoimmune encephalomyelitis (EAE), a model developed in mice that 
simulates human MS, and in vitro studies, suggest that statins have an 
immunomodulatory effect on both T cells and monocytes of immunocompetent cells.8 An 
in vitro study, reported in 2006, reproduced human BBB derived endothelial cells and 
tested the diffusion of bovine serum albumin and [14C]-sucrose across the barrier. The 
study described a 2.39 to a 2.45 fold reduction in permeability of BBB derived 
endothelial cells with the use of statins, as compared to the permeability of BBB derived 
endothelial cells without statins. 4 
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 There was a small open-label trial, conducted in 2003, which used 20mg of lovastatin 
in seven MS patients with active disease. Magnetic resonance imaging (MRI) results 
from these patients indicated a decrease in inflammation with statin treatment. A second 
small open-label trial, conducted in 2004, used 80mg of simvastatin over a six month trial 
that resulted in a decrease in gadolinium (Gd) enhanced lesions.9 In 2005, a study showed 
that the use of statins with glatiramer acitate (GA) or INF-β resulted in a decrease in T-
cell production.10 These trials concluded with the fact, that statins need further testing as 
an adjunct treatment for MS.  
Purpose of Study  
 This topic gives rise to a variety of research that looks at varying outcomes; therefore, 
this study evaluates the results and the quality of the studies in the past four years to 
determine if there could be definitive conclusions drawn regarding the question of the 
efficacy of the use of statins in treating RRMS. 
 Ideally, a double blind randomized control trial (RTC) with a large population might 
provide answers to the efficacy of statins in prolonging the time between relapses in MS, 
but the trials available have small sample sizes and explore varying measured outcomes. 
The trials also vary between animal trials, human RCT, and a post hoc study.  
 This systematic review is designed to look at the human trials and discern what would 
be helpful in a clinical situation, and review the animal trials for background information. 
Clinical Question 
 What is the efficacy of statins in treating relapse-remission multiple sclerosis in 
humans?   
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METHODS  
Search Strategy  
 A systematic review was done by performing an extensive evaluation of literature for 
articles that discuss the use of statins as a treatment for RRMS. Trials considered were 
those published in the last 4 years in which one arm of the study was given a statin and 
the other arm was either given no treatment or a standard MS treatment. Both prospective 
and retrospective studies, published in English, were considered, with a focus on human 
trials.  
 Four databases were searched: MEDLINE, CINAHL, Web of Science, and 
MDConsult. Since this review was for clinical purposes, the key words used were 
multiple sclerosis, statins (MeSH term 3-hydroxy-3-methylglutaryl coenzyme A), and 
MRI. 
Exclusion 
 Vollmer et al8  was excluded because of the date, but also because reviews7,11,13-16 and 
editorials14,15 in the last four years discuss the results. These discussions all lead to the 
same conclusion; there is a need for further trials. Also, there is a more recent trial, Paul 
et al3 that agrees with Vollmer et al, and it has been included in this review. 
 
RESULTS  
 The Summary Matrix of Reviewed Articles gives a brief look at the three studies used 
for this systematic review, including their set-up and conclusions (See Table 2). Detailed 
results of each study are found in this section with a discussion of the findings appearing 
in the next section. 
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Trial One 
 The Birnbaum et al17 trial was a randomized double blind trial. Patients with definite 
RRMS were initially chosen using either Poser criteria (Table 3) or MacDonald criteria 
(Table 4). Participants were then further limited to those on 44µg subcutaneous (SC) 
INF-β three times a week and had been clinically stable for at least 6 months prior to 
selection.17 
 The trial was set-up with three arms. Group one was administered a placebo, the 
second was administered 40mg of atorvastatin, and the third was administered 80mg of 
atorvastatin. The following is a list of the mean values of the clinical and demographic 
characteristics of group one, two and three, respectively:17 
• Age (SD):  40.1 (9.2), 38.4 (7.5), 45.1 (6.3) 
• Duration of disease in years: 7.7 (7), 6.4 (6.7), 7.2 (5.9) 
• EDSS at inclusion (SD, range): 2.3 (1.4, 1-5.5), 2.1 (0.6, 1.5-3), 2.0 (0.7, 1.5-
3.5) 
• No. relapses for 12 months prior to treatment: 1, 0, 0 
 The groups were randomized by giving each participant two unmarked bottles of 
drugs. The groups were instructed to take one pill from each bottle daily. Group one was 
given two bottles of placebo. Group two was given one bottle placebo and one bottle 
40mg atorvastatin. The final group was given two bottles of 40mg atorvastatin. All study 
personnel were unaware as to what each participant received.17  
 The trial started with a pool of 29 individuals. One individual failed due to drug 
related rash, one to a relapse at the time of screening and a third was a voluntary 
withdraw. After screening, only 26 participants entered the randomization for the 9 
12 
 
month trial. Of the 26 that entered, 4 participants were discontinued. After 1 month, a 
participant from group three left due to muscle cramps followed by a relapse that did not 
respond well to steroids. After two months, 1 participant from group 3 left for an 
unknown reason and was lost to follow-up. A participant from group 3 was withdrawn 
after three months due to persistent elevated transaminases. After five months a 
participant from group 1 left due to elevated creatine kinase. All participants that were 
discontinued from the study were accounted for in the analysis.17  
 Participants received treatment for 6 months and were evaluated with MRI and EDSS 
at 0, 3, 6, and 9 months. The neurologists performing the evaluations were also blinded. 
Baseline MRI found one participant with one contrast enhanced lesion (CEL) in groups 
one and two. Group three had two participants with adverse outcomes, one with one CEL 
and one with two CELs.17 
 This trial used analysis of variance (ANOVA) to compare continuous baseline 
covariates. The p-values for the baseline demographics vary from 0.19 for age to 0.91 for 
disease ratio, meaning there is no statistical significance in the baseline demographics of 
the three groups. The trial looked at three outcomes: new CEL on MRI, clinical relapse, 
and both CEL with relapse.17  
 The likelihood of experiencing a CEL, or having a relapse, was determined through 
survival analysis between the placebo and the combined atorvastatin groups. Compared 
to the placebo group, the combined atorvastatin group demonstrated a greater risk for 
experiencing one or more adverse outcomes with a statistically significant p-value of 
0.019. The trial demonstrated that atorvastatin treatment had a hazard ratio of 8.25 
(p=0.044, 95% CI 1.06-64.2).17  
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 At the end of nine months, the combined atorvastatin group had more adverse 
outcomes than the placebo group. The placebo group had no subjects with CEL only, no 
subjects with a clinical relapse only, but one subject did have both a CEL and a clinical 
relapse. The atorvastatin group, taking 40mg, had two subjects with CEL only, one 
subject with a clinical relapse only, and one subject that had both a CEL and a clinical 
relapse. The final group of atorvastatin, taking 80mg, had four subjects with CEL only, 
one subject with a clinical relapse only, and one subject that had both a CEL and a 
clinical relapse.17 
 Of the 17 participants in the combined atorvastatin group, 10 had one or more adverse 
outcomes compared to 1 participant from the 9 placebo subjects (p=0.022). Some of the 
relapses experienced by the participants were the first experienced by that participant in 
years and some were significant enough for steroidal treatment.17  
 This trial concluded that although well tolerated, atorvastatin significantly increased 
the risk of MS disease activity. The trial addresses the facts that lower doses, other statin 
agents, and larger population groups need to be tested to give a more accurate picture, but 
suggests that patients on an interferon and a statin should be monitored closely for 
disease activity and should possibly be changed to another cholesterol lowering agent.17 
Trial Two  
 The Paul et al5 trial was a baseline to treatment study that looked specifically at 
atorvastatin in the treatment of RRMS. The study assessed 80 RRMS patients for certain 
study prerequisites. The patients did not have to have clinically active disease, but they 
needed to fulfill the panel criteria for clinically definite MS including an EDSS (Table 5) 
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score between 0-6, an age between 18-55, and at least one contrast enhanced lesion 
(CEL) on MRI.5   
 The trial was divided into two groups. Group one was treated with atorvastatin and no 
DMD and group two was treated with atorvastatin and INF-β. The following is a list of 
the mean values of the clinical and demographic characteristics of group one and group 
two, respectively:5 
• Age:  37.9 (26-48), 33.9 (19-51) 
• Duration of disease in months: 116.3 (26-317), 63.4 (2-229) 
• EDSS at inclusion (SD, range): 2.50 (1.5, 0-6), 1.14 (1.1, 0-4) 
• Total relapses since disease onset(SD, range): 5.75 (2.6, 3-12), 3 (2.1, 1-10) 
• Relapses 12 months prior to treatment(SD, range): 1.63 (1.3, 0-4), 1.4 (1.0, 0-4) 
 The participants were placed in a group according to their history of DMD use. Group 
one had received DMD with either IFN-b-1a 22 mg SC 3 times weekly or IFN-b-1b SC 
every other day for at least 6 months, the mean being 48 months. Group two had not 
received DMD for at least six months prior to the screening date. Group two was not 
treated with DMDs throughout the study, while group one’s treatment continued for the 
duration of the study.5  
 Of the 80 original participants, 39 were excluded pretrial due to the lack of a CEL on 
the qualifying MRI. Group two contained 25 participants that were allocated to using 
atorvastatin only and group one contained 16 participants that were allocated to 
atorvastatin with their INF-β scheduled treatments. Group two did not lose any 
participants to follow-up, although they had one patient discontinue therapy due to active 
disease. That patient was not included in the analysis. Group one lost one patient to 
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follow-up because of a change in residency. Three participants from group one 
discontinued the study, two from active disease, and one from a sustained increase in 
creatine kinase. These four participants were not included in the analysis.5  
 All the participants were seen 13 times throughout the trial, and received monthly 
MRIs with EDSS evaluations every 3 months. Relapses were treated with 3-5 days of 
1mg of methylprednisolone (MP) administered intravenously, and atorvastatin treatment 
was continued during MP administration.5   
 Statistically, trial two was a two factorial MANOVA design used for a direct 
exploratory comparison, the results of which showed no real statistical difference 
(p=0.274) between group one and group two of the trial. The trial compared several 
outcomes, but the focus of this review is on the MRI and EDSS results. 5 
 Both arms showed improvement of CEL number on T1 MRI with p-values: 0.003 for 
the whole group, 0.060 for group one, and 0.170 for group two. The trial showed 
improvement of CEL volume with p-values: 0.008 for the whole group, 0.062 for group 
one, and 0.140 for group two. The T2 lesion count, on MRI, increased with p-values:  
<0.001 for the whole group, 0.008 for group one, and 0.002 for group two. T2 lesion 
volumes also increased, with p-values: 0.008 for the whole group, 0.003 for group one, 
and 0.053 for group two. EDSS evaluations showed with p-values: 0.665 for the whole 
group, 0.712 for group one, and 0.502 for group two. 5  
 Trial two concluded that 9 months of high-dose atorvastatin is safe and well tolerated 
in RRMS patients, with or without INF-β co-medication. Therefore, the results did not 
suggest statins combination therapy as a superior treatment to the statin monotherapy. 
Also, based on MRI surrogate measures, there is a possible benefit from atorvastatin on 
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lesion formation. The immunomodulatory effects on RRMS that are observed here 
remain to be investigated in future trials. 5 
Trial Three 
 The Rudick et al18 trial was a post hoc analysis of the SENTINEL18 study. The 
SENTINEL study included participants that had experienced at least one relapse during 
the past12-months, then randomized them to receive continued interferon beta-1a in 
combination with 300mg of natalizumab (589 patients) or placebo (582 patients) 
intravenously every 4 weeks for up to 116 weeks. Over a period two years, they looked at 
the rate of clinical relapse per year as well as disability progression sustained for 12 
weeks as measured by EDSS.14 The study also recorded other medications the 
participants were taking, Rudick et al, therefore, looked at the placebo arm of 582 
participants and found that 40 of them were on routine statins of various types.18  
 The post hoc study did not involve any further contact or information gathering from 
the participants. The placebo arm of the SENTINEL study was divided into two arms for 
this study. Group one was 542 participants on intramuscular (IM) INF-β without statins, 
and group two was 40 participants on IM INF-β and statins. The following is a list of the 
mean/median values of the clinical and demographic characteristics of group one and 
two, respectively:18 
• Mean age(SD):  38.7 (7.56), 44.0 (7.15) 
• Median duration of disease in years (range): 8 (1-34), 8 (1-31) 
• Mean EDSS at inclusion (SD): 2.5 (1.13), 2.6 (1.13) 
• Mean no. relapses for 12 months prior to treatment (SD):  1.5 (0.72), 1.4 (0.71) 
• Median CEL per patient (range): 0 (0-16), 0 (0-2) 
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 Of the 40 participants in group two, one participant had an unknown statin start date, 
19 started after the first INF-β was given, and 20 were taking statins prior to the 
randomization date. These start dates lead to a median duration of statin administration at 
657 days with most participants taking atorvastatin (n=26) or simvastatin (n=4) and five 
participants taking multiple statins. Participants in the statin group had a mean age of 5.3 
years older than those in the placebo group; other than the age difference, the participants 
were matched at baseline between the two groups.18 
 Statistically, the cumulative probability of sustained disability progression was 
calculated using the Kaplan-Meier model. Treatment effect was analyzed with the Cox 
proportional hazards model. EDSS was analyzed with an ANOVA model. A Poisson 
regression was used to annualize the relapse rate and the CEL results were analyzed with 
a rank-based ANOVA.18 
 The two year clinical outcomes reveal that groups one and two had no significant 
differences. The adjusted annualized relapse rates are 0.67 for group one and 0.66 for 
group two (p = 0.937). The cumulative probability of sustained disability progression at 
two years had a p-value of 0.438, while the change in EDSS score from baseline had a p-
value of 0.716. CEL count per patient at one year resulted in a p-value of 0.842, and at 
two years, 0.788.18  
 The trial concluded that statins do not have an effect on the efficacy of INF-β. This 
trial compared itself to trial one, and concluded that because of a larger population in 
both arms of the instant trial, it was more accurate.18  
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DISCUSSION  
Trial One 
 The strength of the Birnbaum et al17 trial lies in its randomization and the blinding of 
both participants and study personnel. It also took into account the various doses of 
atorvastatin, using the doses commonly given to lower cholesterol. The trial tracked all of 
the participants and gave a good history as to why they were discontinued. It also 
included all of the participants that started treatment in its outcome analysis. 
 The weaknesses of this trial were that it only tested atorvastatin, it used a small 
population, and it was of short duration. Although it varied the statin dose, it failed to 
give a good picture of the full dose responsiveness of atorvastatin. The demonstrated 
outcomes had the appearance that 80mg was more harmful than 40mg. If 40mg is less 
harmful that 80mg, then would 20mg or even 10mg be less harmful and have a positive 
effect on RRMS? 
 As to the efficacy of statins in treating RRMS, this trial suggested that at these dosage 
levels they are harmful. There is a thought that statins block the STAT1 phosphorylation 
pathway of the interferon.19 Beta interferon and statins affect the immune system along 
different pathways, some of which may be antagonistic to each other. This hypothesis is 
also worthy of further investigation.  
 Trial one disclosed honoraria for several of those conducting the trial from multiple 
sources, and several were above $10,000. 
 Trial Two 
 The Paul et al5  trial’s strengths are in its clinical and demographic characteristics. 
First of all, the trial did well in recording the pretrial condition of the participants, 
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providing a clear picture of both groups and where they were in the disease process. 
Secondly, it covers what happened to those participants that were discontinued. Even 
though they were not included in the analysis, the trial mentioned when they were 
discontinued and what their results were up to the time of leaving. Thirdly, it compared 
its results to previous trials that either agreed with or contradicted its findings. Vollmer, 
et al8 had similar findings and is discussed in several editorials14,15 and reviews. 7,11,13-16 
The Birnbaum et al17 trial above, contradicted the findings.  
 The Paul et al5 trial had its weaknesses. Participants were not randomized. The 
participants were grouped solely by where they are in their disease progression, which 
can be seen in the demographic characteristics of the trial. This placed those participants 
that are further along in their disease progression into the INF-β group. The trial was not 
blinded, which may have impacted EDSS evaluations of the patients and the 
neurologist’s interpretation of the MRIs. This may not affect the outcomes by a large 
margin, since all participants were taking atorvastatin, but there is room for bias, which 
should be taken into consideration. Only one type of statin was used and only at one 
dosage. Statins have differing pharmacological properties,17 therefore their interactions 
with INF-β may vary. It is interesting that Paul et al found 80mg to not be harmful, when 
Birnbaum et al found 80mg to be more harmful than 40mg. 
 Finally, the duration and total number of participants were weaknesses. Trial two was 
larger than trial one, but it still only had 41 participants and was just a nine month study. 
 As to the efficacy of statins in treating RRMS, this trial suggests that they are 
effective. It is notable that there are different results from this trial compared to trial one. 
Why are the outcomes of these trials the exact opposite?  
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 Trial two disclosed honoraria for several of the people conducting the trial from 
multiple sources, but no amounts were disclosed. 
Trial Three 
 The Rudick et al18 trial was strong in places that other two trials are weak. It was 
conducted over a two year period and had a larger population of participants. The study 
was post hoc, but the original study was randomized. Although the placebo group 
contained 542 participants and the statin group contained 40, the groups were well 
matched at baseline for disease severity. Since, the statin group was taking various statins 
in different doses as prescribed by their personal physicians for cholesterol therapy, this 
helped in providing a more complete look at the effect of statins on INF-β, but there was 
no real control over what type of statin was used or in what dose. Even though the 
original trial was randomized, the determination of which participants would take statins 
was not randomized.  
 As to the efficacy of statins in treating RRMS, this trial suggested that they are not 
effective. 
 Trial three did not list any disclosures. 
 
CONCLUSION  
 The decision of how effective statins are as a DMD in the treatment of RRMS has not 
been resolved. There have been many advances contributing to the knowledge of the 
cellular and humoral immune responses and their relationship to MS. The use of statins to 
target elements of the immunological cascade could be advantageous over currently 
available drugs.13 
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 In response to the clinical question of this paper, these three studies have completely 
different answers. The sample sizes and duration of the trials can be large contributors to 
the disparities of the results, but the varying statin dosages and the assorted types of 
statins may also be contributors. Trial one used varying dosages of atorvastatin, trial two 
used only 80mg of atorvastatin, and trial three had varying dosages of assorted statins.  
 Financing and other limitations can also alter the trial. Avoiding bias from drug 
companies can lead to small trials with a short duration, but clinically, there is no 
substitute for a large, randomized controlled trial that takes 2-3 years. 
 When looking at the weaknesses of the trials, the conclusion would be a need for one 
or more trials that are based on the idea of the use of statins as a DMD in RRMS. These 
differing trials can provide a unique opportunity to setup a new trial. 
 The ultimate trial would have an extremely large sample size, with each arm having 
between 200 and 300 participants.  It would need to be randomized and double blinded. 
The patients would also have to have an extensive inclusion and exclusion criteria. The 
patients would need to be at about the same place in their RRMS disease state. The Poser 
or MacDonald criteria, used in trial two, would be a good evaluation tool for the patient’s 
disease state determination. 
 Since MS is a cyclic relapse – remitting disease, a three to five year study would also 
be advantageous. RRMS patients have differing disease cycles. During short time 
duration trials, it is difficult to distinguish the cause of a patient’s relapse. Is the relapse 
due to an adverse reaction to the treatment being tested or is it due to their natural RRMS 
cycle? 
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 There would be multiple arms in such a trial. One arm would be a true placebo group 
that received no treatments at all. This would help to determine what outcomes will 
possible occur in the natural progression of the RRMS patient. There would also need to 
be multiple arms at each of the statin types, and each of the statin dosages, with multiple 
arms for the INF-β. This would mean two arms per dose, per type of statin. There would 
be an arm for INF-β by itself, and one with each statin, at each dosage. Lastly, there 
would be an arm for each statin at each dose, without INF-β.  
 The outcomes would also need to be controlled. Since the ultimate goal is for clinical 
treatment of RRMS patients, the outcome should measure disease progression. The 
patient cares most about quality of life, therefore; the EDSS score is a good place to start. 
The next logical outcome would be number of relapses over the study’s duration. 
Relapses are one of the ways that patients determine progression of disease, and it is after 
a relapse that the patient’s disability baseline may shift. Finally CEL on MRI is a good 
outcome. Although this is not directly related to a relapse, the total number of CELs on 
MRI is a hallmark for future progression of MS. 
  There are more trials in progress that are attempting to address some of these issues. 
For example, the Orefice, G. et. al. trial is conducting a 2 year study with 20mg of 
atorvastatin in conjunction with INF-β that should be out sometime in 2010.20, 21 With the 
difficulties of the current DMDs for RRMS, the search for something safer and more 
affective will continue.  
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Table 1 – Diagnostic description of the types of Multiple Sclerosis1 
Name Discription 
Benign Only a few attacks with little or no disability after 20 years 
Primary – Progressive 
Multiple Sclerosis (PPMS) 
Gradual, but steady accumulation of 
neurological deficits from onset 
Secondary – Progressive 
Multiple Sclerosis (SPMS) 
Progressive worsening of symptoms with 
or without superimposed relapses 
Progressive – Relapsing 
Multiple Sclerosis (PRMS) 
Progressive coarse from the onset, 
sometimes combined with occasional acute 
symptom flare-ups 
Malignant or Fulminant 
Multiple Sclerosis  Rapidly progressive disease coarse 
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Table 2 – Summary of matrix 
Author/  Title/ 
Journal 
Yr. Patients/ Intervention Comparison Outcome(s) Study type 
pub Population 
Birnbaum et al13 2008 
Dx RRMS 
Adults, on 
standard 
high-dose 
subcutaneous 
interferon 
beta-1a 
INF-B, 40mg 
or 80mg 
Atorvastatin 
INF-B only 
CEL on MRI only, Relapse only, and 
both 
RCT 
Paul et al3 2008 
DX RRMS 
Adults age 
18-55, EDSS 
0-6, at least 
one CEL on 
MRI 
INF-B and 
80mg of 
Atorvastatin 
80mg 
Atorvastatin 
EDSS and MSFC scores, CEL on MRI, 
CBC, electrolytes, creatinine, 
creatinine kinase, and lipids 
baseline-to-treatment trial was 
designed to evaluate the safety, 
tolerability and efficacy of orally 
administered atorvastatin in patients 
with RRMS 
Rudick et al14 2009 
DX RRMS 
Adults taking 
IM IFN-B-1a 
Statins No statins 
2-year endpoints, including 
cumulative probability of sustained 
disability progression 
as defined in the SENTINEL study4; 
rate of clinical relapse; 
number of new or enlarging T2-
hyperintense lesions; and number 
of gadolinium-enhancing (Gd ) 
lesions.4 
post hoc analysis of data from the 
Safety and Efficacy of Natalizumab in 
Combination With IFN -1a in Patients 
With Relapsing-Remitting Multiple 
Sclerosis (SENTINEL) study 
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Table 3 – Poser criteria22 used to give a diagnostic level to MS 
Diagnosis Criteria 
Clinically probable MS 
 
• 2 attacks and clinical evidence of 1 
lesion, or 
• 1 attack and clinical evidence of 2 
separate lesions, or 
• 1 attack, clinical evidence of 1 lesion, 
and paraclinical evidence of another 
separate lesion 
Laboratory supported probable MS •    2 attacks and CSF abnormalities 
Clinically definite MS 
• 2 attacks and clinical evidence of 2 
separate lesions, or 
• 2 attacks, clinical evidence of one and 
paraclinical evidence of another 
separate lesion 
Laboratory supported Definite MS 
• 2 attacks, either clinical or paraclinical 
evidence of 1 lesion, and 
cerebrospinal fluid (CSF) immunologic 
abnormalities, or 
• 1 attack, clinical evidence of 2 
separate lesions & CSF abnormalities, 
or 
• 1 attack, clinical evidence of 1 and 
paraclinical evidence of another 
separate lesion, and CSF 
abnormalities 
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Table 4 – McDonald criteria23 used to give standards for making a diagnosis 
 
Relapses Clinical Lesions Additional requirements 
2 or more 2 or more None; clinical evidence will suffice  
(additional evidence desirable but must be consistent with MS) 
2 or more 1 
Dissemination in space, demonstrated by MRI, or a positive CSF 
and 2 or more MRI lesions consistent with MS, or further clinical 
attack involving different site 
1 2 or more Dissemination in time, demonstrated by MRI, or second clinical 
attack 
1 1 
Dissemination in space by demonstrated by MRI, or positive CSF 
and 2 or more MRI lesions consistent with MS and  
Dissemination in time demonstrated by MRI, or second clinical 
attack 
An insidious neurological 
progression suggestive of MS 
Positive CSF andDissemination in space demonstrated by MRI 
evidence of 9 or more T2 brain lesions, or 2 or more spinal cord 
lesions, or 4-8 brain and 1 spinal cord lesion, or positive visually 
evoked response (VEP) with 4-8 MRI lesions, or positive VEP with 
<4 brain lesions plus 1 spinal cord lesion and Dissemination in 
time demonstrated by MRI, or continued progression for 1 year 
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Table 5 – Expanded Disability Status Scale (EDSS) 24 
Score Definition 
0.0 Normal neurological exam. 
1.0 No disability, but minimal signs in one functional system (FS) are present. 
1.5 No disability, but minimal signs in more than one FS are present. 
2.0 Minimal disability in one FS is present. 
2.5 There is mild disability in one FS or minimal disability in two FS. 
3.0 There is moderate disability in one FS or mild disability in three or four FS. However, the person is still fully ambulatory. 
3.5 The person is fully ambulatory, but has moderate disability in one FS and mild disability in one or two FS; or moderate disability in two FS; or mild disability in five FS. 
4.0 The person is fully ambulatory without aid, and is up and about most of the day (12 hours) despite relatively severe disability. He or she is able to walk 500 meters without aid or rest. 
4.5 
The person is fully ambulatory without aid, and is up and about much of day. He or she is able to work a 
full day, but may otherwise have some limitations of full activity or require minimal assistance. This is 
considered relatively severe disability. Able to walk 300 meters without aid. 
5.0 The person is able to walk 200 meters without aid or rest. Disability impairs full daily activities, such as working a full day without special provisions. 
5.5 The person is able to walk 100 meters without aid or rest. Disability precludes full daily activities. 
6.0 The person needs intermittent or unilateral constant assistance (cane, crutch or brace) to walk 100 meters with or without resting. 
6.5 The person needs constant bilateral support (cane, crutch or braces) to walk 20 meters without resting. 
7.0 
The person is unable to walk beyond five meters even with aid, and is essentially restricted to a 
wheelchair. However, he or she wheels self and transfers alone, and is active in wheelchair about 12 
hours a day. 
7.5 The person is unable to take more than a few steps and is restricted to wheelchair, and may need aid to transfer. He or she wheels self, but may require a motorized chair for a full day's activities. 
8.0 The person is essentially restricted to bed, a chair or a wheelchair, but may be out of bed much of day. He or she retains self care functions and has generally effective use of arms. 
85. The person is essentially restricted to bed much of day, but has some effective use of arms and retains some self care functions. 
9.0 The person is confined to bed, but still able to communicate and eat. 
9.5 The person is totally helpless and bedridden and is unable to communicate effectively or eat and swallow.  
10.0 Death due to MS. 
 
 
 
 
 
